Procter & Gamble Health Ltd
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]
- Market Cap ₹ 8,512 Cr.
- Current Price ₹ 5,120
- High / Low ₹ 5,836 / 4,637
- Stock P/E 37.6
- Book Value ₹ 324
- Dividend Yield 1.17 %
- ROCE 45.0 %
- ROE 33.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.1%
- Company has been maintaining a healthy dividend payout of 110%
Cons
- Stock is trading at 15.8 times its book value
- The company has delivered a poor sales growth of 6.28% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Part of BSE Healthcare BSE 250 SmallCap Index BSE Allcap BSE SmallCap BSE 500
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
798 | 867 | 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 1,160 | |
721 | 809 | 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 828 | |
Operating Profit | 77 | 59 | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 331 |
OPM % | 10% | 7% | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 29% |
21 | 20 | 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | -7 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
Depreciation | 10 | 13 | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 27 |
Profit before tax | 88 | 67 | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 297 |
Tax % | 37% | 35% | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | |
56 | 43 | 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 218 | |
EPS in Rs | 33.66 | 26.04 | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 131.18 |
Dividend Payout % | 25% | 23% | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% |
Compounded Sales Growth | |
---|---|
10 Years: | 4% |
5 Years: | 6% |
3 Years: | 5% |
TTM: | -6% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | -24% |
3 Years: | 7% |
TTM: | -2% |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | 4% |
3 Years: | 1% |
1 Year: | -1% |
Return on Equity | |
---|---|
10 Years: | 28% |
5 Years: | 27% |
3 Years: | 32% |
Last Year: | 33% |
Balance Sheet
Figures in Rs. Crores
Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
Reserves | 506 | 538 | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | |
125 | 154 | 192 | 215 | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | |
Total Liabilities | 648 | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 |
85 | 110 | 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | |
CWIP | 9 | 28 | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 |
Investments | 24 | 24 | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
530 | 547 | 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | |
Total Assets | 648 | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 |
Cash Flows
Figures in Rs. Crores
Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 5 | 83 | 107 | 54 | -130 | 235 | 247 | 170 | 236 | 228 | ||
7 | 11 | -68 | -75 | -48 | 1,270 | 165 | -32 | -26 | -22 | -7 | ||
-5 | -17 | -12 | -15 | -22 | -30 | -883 | -387 | -289 | -98 | -418 | ||
Net Cash Flow | 3 | -1 | 4 | 17 | -16 | 1,109 | -483 | -172 | -145 | 116 | -197 |
Ratios
Figures in Rs. Crores
Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 38 | 44 | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 |
Inventory Days | 153 | 162 | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 |
Days Payable | 37 | 40 | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 |
Cash Conversion Cycle | 154 | 166 | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 |
Working Capital Days | 70 | 74 | 69 | 52 | 94 | 42 | 22 | 23 | 9 | 18 | 16 | 20 |
ROCE % | 18% | 12% | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
1d - Information on loss of share certificates.
- Reg. 34 (1) Annual Report. 13 Nov
- Annual Report And Notice Calling The 57Th Annual General Meeting Of The Company For The Financial Year Ended June 30, 2024 13 Nov
-
Business Responsibility and Sustainability Reporting (BRSR)
13 Nov - Submission of Business Responsibility & Sustainability Report for FY 2023-24.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
4 Nov - Procter & Gamble Health reports Q1 results for FY2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Strong Brand Portfolio
Company is one the India’s largest VMS companies, manufacturing and marketing vitamins, minerals and supplements. It has a strong portfolio of various pharma brands such as Evion, Neurobion, Seven seas, Nasivion, Polybion, Cosome and Livogen. [1]